MSA
This asset is not currently listed on any markets available through Pearler. The information on this page may be inaccurate or out of date.
🇦🇺 ASX
👑 Overview
📈 Performance
💵 Cost
🍃 Esg
🤓 Advanced
👨👩👧👦 Community
📈
N/A
Annual Growth
5 years average annual growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
0
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Mysale Group PLC
📈 Performance
Price History
N/A
1M
All Time
Graph
Table
Performance graph isn't available yet for this share
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in MSA
0
📊 Total Capital Earnings
N/A
🔃 Average investment frequency
N/A
💵 Average investment amount
N/A
⏰ Last time a customer invested in MSA
N/A
MSA investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
50k - 100k
Less than 50k
👶 Age of investors
18 - 25
26 - 34
35 - 90
🙋 Legal gender of investors
Female
Male
Pearlers who invest in MSA also invest in...
Want more shares? Try these...
Mesoblast Ltd. is a biopharmaceutical company, which engages in the research, development, and market of mesenchymal lineage adult stem cell technology platform. The company is headquartered in Melbourne, Victoria and currently employs 73 full-time employees. The company went IPO on 2004-12-16. The company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. The company is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. The company has established commercial partnerships in Europe and China for certain Phase III assets.
🙌 Performance (5Yr p.a)
0.54%
📊 Share price
$2.66 AUD
🧬 BIOTECHNOLOGY
Mont Royal Resources Ltd. engages in the acquisition, exploration, and development of mineral resource projects. The company is headquartered in Sydney, New South Wales. The company went IPO on 2019-05-07. The projects are located in the emerging James Bay Area, a tier-1 mining jurisdiction of Quebec, Canada, and are prospective for lithium, precious (gold, silver) and base metals mineralization (copper, nickel). The Northern Lights Projects are located over 300 kilometers (km) NNE of the town of Chibougamau and 56 km south of Renard Diamond mine. The projects include the Northern Lights Assets (75%-owned), Leran Project (option to own 75%), Dios Assets (JV to earn-in 70%) across a total land package of 536 square kilometers (km2). The firm has a joint venture (JV) option agreement with Azimut Exploration Inc., to earn-in up to 70% of the Wapatik Gold-Copper Nickel Project, which covers approximately 220 claims totaling 115 km2 in continuous tenure, located in the James Bay Area, Quebec, Canada.
🙌 Performance (5Yr p.a)
-16.43%
📊 Share price
$0.04 AUD
⛏️ MINING